News | September 20, 2011

Study Shows Fluid Monitoring in HF Patients Leads to Increased Hospital Visits


September 20, 2011 – A recent study sought to determine if monitoring fluid build-up in the chest of heart failure patients would lead to earlier detection of problems and prevent repeat hospitalizations. The results, released as part of the late-breaking trials at the 15th annual scientific meeting of the Heart Failure Society of America (HFSA), actually showed an increase in hospital visits.

D.J. van Veldhuisen, M.D., UMC Groningen, the Netherlands, presented the results.

Fluid builds up in the heart, which is unable to manage the increase in fluid. This results in patients requiring a hospital stay to correct the issue. The problem can cause weight gain, fatigue and shortness of breath.

The study focused on strategies for early detection of fluid overflow in order to avoid lengthy and costly hospital stays. Doctors studied 350 patients who had implantable cardioverter defibrillators (ICDs) with or without cardiac resynchronization; they were fitted with diagnostic systems to monitor intrathoracic impedance, which reflects fluid in the chest, a sign of (impeding) decompensation.

The systems are designed to emit a beep when fluid levels reach a certain threshold, signaling the patient to contact their doctor.

Doctors sought to determine if these systems would provide detection early enough to prevent the need for later hospitalization. The patients who were fitted with active diagnostic systems actually saw an increase in hospital visits, rather than the decrease doctors had hoped for.

As van Veldhuisen points out, patients may have become nervous about the alarm going off, which resulted in visits to the hospital rather than a phone call to their doctor. He also notes the human body naturally fluctuates from day to day, so the question becomes how quickly should doctors respond to slight changes

"Early detection of fluid buildup is the key to reducing hospital stays and improving quality of life for patients," van Veldhuisen said. "This study, among others, is aimed at finding the best ways to identify problems early, and monitoring patients remotely seems to be the best option. The question becomes which method we should use to monitor patients."

For more information: www.abouthf.org


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now